Next 10 |
home / stock / annx / annx articles
U.S. stocks were higher, with the Nasdaq Composite index gaining around 100 points on Friday. Shares of The Bank of New York Mellon Corporation (NY...
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Or...
Single Infusion of ANX005 Demonstrated Significant Improvements Across Multiple Functional and Prognostic Measures That Expedited Recovery in GBS ...
Shares of Stitch Fix, Inc. (NASDAQ:SFIX) rose sharply in today's pre-market trading following better-than-expected third-quarter financial res...
U.S. stocks turned higher toward the end of trading, with the Dow Jones gaining around 200 points on Tuesday. The Dow traded up 0.53% to 38,774.55 ...
Shares of Core & Main Inc (NYSE:CNM) fell sharply during Tuesday's session after the company reported mixed first-quarter financial result...
On Tuesday, Annexon Inc (NASDAQ:ANNX) released topline results from its Phase 3 trial in patients with Guillain-Barré syndrome (GBS), an autoimmun...
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 50 points on Tuesday. The Dow traded down 0.14% to 38,516.7...
U.S. stocks were mixed, with the Dow Jones index gaining around 20 points on Tuesday. Shares of Saia Inc (NASDAQ:SAIA) rose sharply during today...
News, Short Squeeze, Breakout and More Instantly...
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation Topline Phase 2 ARCHER Trial Results Will be Discussed as an Oral Presentation BRISBANE, Calif., July 11, 2024 (GLOBE N...
ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints Two and a Half Times More ANX005-Treated Patients Returned to a Normal / Pre-Disease State of Health Over Placebo on GBS-DS by Week 26, Increa...
Single Infusion of ANX005 Demonstrated Significant Improvements Across Multiple Functional and Prognostic Measures That Expedited Recovery in GBS Patients ANX005 Has Potential to be the First Targeted Therapy Approved for the Treatment of GBS BRISBANE, Calif., June 18, 2024 (GLOBE...